

# Concizumab for treating haemophilia A or B in people 12 years and over with factor inhibitors (terminated appraisal)

Technology appraisal guidance

Published: 27 January 2026

[www.nice.org.uk/guidance/ta1124](https://www.nice.org.uk/guidance/ta1124)

# Contents

Advice.....	3
Information.....	3

## Advice

NICE is unable to make a recommendation about the use in the NHS of concizumab for treating haemophilia A or B in people 12 years and over who have factor inhibitors. This is because Novo Nordisk has confirmed that it does not intend to make an evidence submission for the appraisal.

Novo Nordisk considers that there is not enough evidence to provide an evidence submission for this appraisal. Because of the small size of the eligible population, there is a high degree of uncertainty in the observational evidence base that would be used to inform an economic model suitable for decision making.

## Information

If NHS organisations wish to consider concizumab for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-8425-1